203 related articles for article (PubMed ID: 10526666)
41. Sex steroid hormones and genetic susceptibility to breast and prostate cancer.
Feigelson HS; Ross RK; Yu MC; Coetzee GA; Reichardt JK; Henderson BE
Drug Metab Rev; 1998 May; 30(2):421-34. PubMed ID: 9606611
[No Abstract] [Full Text] [Related]
42. Improving surveillance and quality of life of BRCA mutation carriers.
Loman N; Borg A
J Clin Oncol; 2010 Aug; 28(22):e376-7. PubMed ID: 20458044
[No Abstract] [Full Text] [Related]
43. Genetic counseling for BRCA1/BRCA2 testing.
Schneider KA
Genet Test; 1997; 1(2):91-8. PubMed ID: 10464632
[TBL] [Abstract][Full Text] [Related]
44. Oral contraceptives and hereditary ovarian cancer.
de Souza RM; Lazzaron AR
N Engl J Med; 1999 Jan; 340(1):59; author reply 60. PubMed ID: 9882211
[No Abstract] [Full Text] [Related]
45. BRCA1/BRCA2 mutations and breast cancer in Ashkenazi Jewish women.
Gilbert F; Dabney MK; Diemer K; Ludwig S; Rosenthal G; Osborne MP
Ann N Y Acad Sci; 1997 Dec; 833():198-203. PubMed ID: 9616755
[No Abstract] [Full Text] [Related]
46. Ethical aspects of genetic counseling in familial breast and ovarian cancer. Combining applied theory and reflective practice.
Goelen G; Rigo A; Neyns B; Betz W; De Grève J
Ann N Y Acad Sci; 1997 Dec; 833():170-2. PubMed ID: 9616750
[No Abstract] [Full Text] [Related]
47. Genetic testing for breast cancer predisposition.
Gauthier-Villars M; Gad S; Caux V; Pagès S; Blandy C; Stoppa-Lyonnet D
Surg Clin North Am; 1999 Oct; 79(5):1171-87, xxi. PubMed ID: 10572557
[TBL] [Abstract][Full Text] [Related]
48. BRCA1/2 carriers and endocrine risk modifiers.
Eeles R; Kadouri L
Endocr Relat Cancer; 1999 Dec; 6(4):521-8. PubMed ID: 10730905
[No Abstract] [Full Text] [Related]
49. Breast cancer in carriers of BRCA1 and BRCA2 mutations: tackling a molecular and clinical conundrum.
Haber DA
J Clin Oncol; 1999 Nov; 17(11):3367-70. PubMed ID: 10550129
[No Abstract] [Full Text] [Related]
50. Preventing inherited ovarian cancer.
Health News; 1998 Sep; 4(11):7. PubMed ID: 9745394
[No Abstract] [Full Text] [Related]
51. Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers.
Johannsson O; Loman N; Borg A; Olsson H
Lancet; 1998 Oct; 352(9137):1359-60. PubMed ID: 9802282
[No Abstract] [Full Text] [Related]
52. A polymorphic stop codon in BRCA2.
Mazoyer S; Dunning AM; Serova O; Dearden J; Puget N; Healey CS; Gayther SA; Mangion J; Stratton MR; Lynch HT; Goldgar DE; Ponder BA; Lenoir GM
Nat Genet; 1996 Nov; 14(3):253-4. PubMed ID: 8896551
[No Abstract] [Full Text] [Related]
53. Coming to grips with genes and risk.
Kahn P
Science; 1996 Oct; 274(5287):496-8. PubMed ID: 8928001
[No Abstract] [Full Text] [Related]
54. Genetics of breast cancer--an update.
Lanier AP; Kaplan SD
Alaska Med; 1995; 37(2):54-8. PubMed ID: 7661327
[No Abstract] [Full Text] [Related]
55. Chemoprevention of hereditary ovarian cancer.
Rubin SC
N Engl J Med; 1998 Aug; 339(7):469-71. PubMed ID: 9700183
[No Abstract] [Full Text] [Related]
56. [Update on genetic markers of cancer].
Janoueix-Lerosey I; Delattre O
Bull Cancer; 1999 Jan; 86(1):15-21. PubMed ID: 10029699
[No Abstract] [Full Text] [Related]
57. The BRCA paradox in breast and ovarian cancer.
Ponzone R; Baum M
Eur J Cancer; 1998 Jun; 34(7):966-7. PubMed ID: 9849441
[No Abstract] [Full Text] [Related]
58. Evaluation of the needs of male carriers of mutations in BRCA1 or BRCA2 who have undergone genetic counseling.
Liede A; Metcalfe K; Hanna D; Hoodfar E; Snyder C; Durham C; Lynch HT; Narod SA
Am J Hum Genet; 2000 Dec; 67(6):1494-504. PubMed ID: 11063672
[TBL] [Abstract][Full Text] [Related]
59. BRCA1 and BRCA2 testing: weighing the demand against the benefits.
Devilee P
Am J Hum Genet; 1999 Apr; 64(4):943-8. PubMed ID: 10090879
[No Abstract] [Full Text] [Related]
60. Population genetics of BRCA1 and BRCA2.
Szabo CI; King MC
Am J Hum Genet; 1997 May; 60(5):1013-20. PubMed ID: 9150148
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
